Larimar Therapeutics, Inc.
LRMR
$4.36
$0.092.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -72.98% | -74.32% | -105.54% | -103.79% | -71.05% |
| Total Depreciation and Amortization | -7.67% | 0.00% | 10.06% | 5.59% | 0.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 71.59% | 102.93% | 49.96% | 41.67% | -18.03% |
| Change in Net Operating Assets | 187.81% | 455.24% | 662.70% | 1,012.97% | -66.96% |
| Cash from Operations | -68.96% | -51.08% | -59.98% | -65.54% | -114.90% |
| Capital Expenditure | 50.49% | 92.55% | 82.33% | 46.00% | 29.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -30.98% | 5,813.72% | 218.30% | 180.38% | 144.36% |
| Cash from Investing | -30.91% | 4,560.62% | 217.48% | 179.75% | 144.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 262,630.30% | 262,630.30% | -59.75% | -59.72% | -99.96% |
| Repurchase of Common Stock | -- | 39.82% | 39.82% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 261,666.67% | 64,727.24% | -59.79% | -59.64% | -99.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 677.59% | 274.73% | 809.94% | 1,587.14% | 79.91% |